Isamu Okamoto

Summary

Affiliation: Kinki University
Country: Japan

Publications

  1. ncbi request reprint Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
    Masahiko Ando
    Department of Preventive Services, Kyoto University School of Public Health, Kyoto, Japan
    J Clin Oncol 24:2549-56. 2006
  2. doi request reprint Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.
    Masayuki Takeda
    Clin Lung Cancer 13:157-9. 2012
  3. pmc Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
    W Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 105:407-12. 2011
  4. pmc Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
    J Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 105:807-13. 2011
  5. pmc Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
    K Takezawa
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 104:1594-601. 2011
  6. pmc Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group
    Ketan Badani
    Department of Urology, Columbia University, New York, NY, USA
    Oncotarget 4:600-9. 2013
  7. pmc Identification of thymidylate synthase as a potential therapeutic target for lung cancer
    K Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 103:354-61. 2010
  8. pmc Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
    T Iwasa
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 103:36-42. 2010
  9. pmc Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
    J Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 106:763-7. 2012
  10. pmc Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
    Y Akashi
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 98:749-55. 2008

Collaborators

Detail Information

Publications100

  1. ncbi request reprint Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
    Masahiko Ando
    Department of Preventive Services, Kyoto University School of Public Health, Kyoto, Japan
    J Clin Oncol 24:2549-56. 2006
    ..We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of the drug in Japanese with non-small-cell lung cancer (NSCLC)...
  2. doi request reprint Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.
    Masayuki Takeda
    Clin Lung Cancer 13:157-9. 2012
  3. pmc Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
    W Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 105:407-12. 2011
    ....
  4. pmc Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
    J Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 105:807-13. 2011
    ..MET is a receptor tyrosine kinase (RTK) whose gene is amplified in various tumour types. We investigated the roles and mechanisms of RTK heterodimerisation in lung cancer with MET amplification...
  5. pmc Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
    K Takezawa
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 104:1594-601. 2011
    ..We have now investigated the effect of TS overexpression on pemetrexed sensitivity in NSCLC cells...
  6. pmc Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group
    Ketan Badani
    Department of Urology, Columbia University, New York, NY, USA
    Oncotarget 4:600-9. 2013
    ..Improved risk prediction models using genomic information may enable clinicians to better weigh the risk of metastasis and the morbidity and costs of treatment in a clinically heterogeneous population...
  7. pmc Identification of thymidylate synthase as a potential therapeutic target for lung cancer
    K Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 103:354-61. 2010
    ..Although inhibition of TS has an antiproliferative effect in cancer cells, the precise mechanism of this effect has remained unclear...
  8. pmc Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
    T Iwasa
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 103:36-42. 2010
    ..We have now investigated the effects of the combination of YM155, a novel small-molecule inhibitor of survivin expression, and platinum compounds (cisplatin and carboplatin) on human non-small cell lung cancer (NSCLC) cell lines...
  9. pmc Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
    J Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 106:763-7. 2012
    ....
  10. pmc Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
    Y Akashi
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Br J Cancer 98:749-55. 2008
    ..Nimotuzumab enhanced the antitumor efficacy of radiation in certain human NSCLC cell lines in vitro and in vivo. This effect may be related to the level of EGFR expression on the cell surface rather than to EGFR mutation...
  11. doi request reprint Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Invest New Drugs 31:1275-82. 2013
    ..This study prospectively evaluated the efficacy and safety of pemetrexed and carboplatin followed by maintenance pemetrexed in chemo-naïve patients with advanced nonsquamous non-small cell lung cancer (NSCLC)...
  12. doi request reprint Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    Cancer Sci 103:1391-6. 2012
    ..Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed...
  13. doi request reprint Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC
    Masayuki Takeda
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Jpn J Clin Oncol 42:528-33. 2012
    ..Subsequent chemotherapy has not been optimized in such patients...
  14. doi request reprint Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Invest New Drugs 30:1132-7. 2012
    ....
  15. doi request reprint Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan
    J Thorac Oncol 7:427-33. 2012
    ..An open-label, single-arm, phase I study was performed to evaluate escalating doses of TSU-68 in combination with standard chemotherapy in patients with advanced non-small cell lung cancer...
  16. pmc Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 30:639-46. 2012
    ..We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed for treatment of advanced refractory solid tumors...
  17. doi request reprint Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Int J Clin Oncol 13:112-6. 2008
    ..This overview of ongoing trials highlights new directions in the treatment of locally advanced NSCLC...
  18. doi request reprint Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin
    Kunio Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Osaka 589 8511, Japan
    Mol Cancer Ther 11:204-13. 2012
    ..They further suggest that the targeting of survivin has the potential to overcome EGFR-TKI resistance in EGFR mutation-positive NSCLC...
  19. doi request reprint Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Lung Cancer 72:199-204. 2011
    ....
  20. doi request reprint Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:2825-33. 2010
    ..In conclusion, the maximum tolerated dose of BIBF 1120 in the current study was determined to be 200 mg twice daily, and our biomarker analysis indicated that this angiokinase inhibitor is biologically active...
  21. doi request reprint S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Clin Lung Cancer 10:290-4. 2009
    ..Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC...
  22. doi request reprint Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
    Isamu Okamoto
    Kinki University Faculty of Medicine, Osaka City General Hospital, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    J Clin Oncol 28:5240-6. 2010
    ....
  23. doi request reprint Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Clin Cancer Res 14:5250-4. 2008
    ..To evaluate the efficacy and toxicity of combination therapy with the oral fluoropyrimidine formulation S-1 and irinotecan for patients with advanced NSCLC...
  24. pmc Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Invest New Drugs 28:844-53. 2010
    ..This phase I trial was conducted to evaluate drug safety and pharmacokinetics as well as tumor response of sorafenib in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)...
  25. pmc Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:17-23. 2010
    ..To determine the pharmacokinetics and safety of RAD001 (everolimus) in Japanese patients with advanced solid tumors...
  26. doi request reprint Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients
    Kunio Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:54-9. 2010
    ..The optimal management of elderly patients with limited-disease small cell lung cancer (LD-SCLC) has not been established...
  27. doi request reprint Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    FEBS J 277:309-15. 2010
    ..This minireview summarizes the emerging role of molecular profiling in guiding the clinical use of anti-EGFR therapeutic agents...
  28. doi request reprint Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Jpn J Clin Oncol 40:222-6. 2010
    ..However, little is known about changes in the GH-IGF-1 axis in cancer patients...
  29. doi request reprint Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 70:168-73. 2010
    ..The primary objectives of this study were to determine the recommended dose of pemetrexed and carboplatin in patients with chemo-naive advanced non-small cell lung cancer (NSCLC)...
  30. doi request reprint Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:1647-56. 2010
    ..The addition of TS-targeting drugs to BIBW2992 is a promising strategy to overcome EGFR-TKI resistance in NSCLC with the T790M mutation of EGFR...
  31. doi request reprint Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines
    Tsutomu Iwasa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Clin Cancer Res 14:6496-504. 2008
    ..We have now investigated the effect of YM155, a small-molecule inhibitor of survivin expression, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to gamma-radiation...
  32. doi request reprint Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition
    Wataru Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:1188-97. 2010
    ..Our results suggest that c-Src is a promising target for the treatment of gastric cancer and that analysis of MET amplification might optimize patient selection for treatment with c-Src inhibitors...
  33. doi request reprint Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Japan
    Clin Cancer Res 15:907-13. 2009
    ..We have now investigated whether addition of the oral fluoropyrimidine derivative S-1 to gefitinib might overcome gefitinib resistance in NSCLC cell lines...
  34. doi request reprint Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification
    Junko Tanizaki
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:1198-207. 2010
    ..Our preclinical findings thus indicate that the combination of S-1 and HER2-targeting agents is a promising treatment option for gastric cancer with HER2 amplification...
  35. doi request reprint Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Cancer Sci 101:167-72. 2010
    ..These results provide a rationale for clinical targeting of Src in gefitinib-resistant NSCLC with MET amplification...
  36. doi request reprint Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Sakai Hospital, Osaka, Japan
    Cancer Res 69:6515-21. 2009
    ..Our results thus suggest that sorafenib inhibits NSCLC cell growth by targeting B-RAF in cells with wild-type KRAS and C-RAF in those with mutant KRAS...
  37. doi request reprint Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification
    Wataru Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 11:1557-64. 2012
    ..Crizotinib thus shows a marked antitumor action both in vitro and in vivo specifically in gastric cancer cells positive for MET amplification...
  38. doi request reprint De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer
    Masayuki Takeda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 5:399-400. 2010
    ..We examined whether the mutational status of KRAS might be associated with primary resistance to EGFR-TKIs in EGFR mutation-positive patients with NSCLC...
  39. doi request reprint Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer
    Junko Tanizaki
    Department of Medical Oncology and Genome Biology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    Clin Cancer Res 18:6219-26. 2012
    ..However, acquired resistance to these agents has already been described in treated patients, and the mechanisms of such resistance remain largely unknown...
  40. ncbi request reprint Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Int J Cancer 122:1530-8. 2008
    ....
  41. ncbi request reprint Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer
    Tomohiro Ozaki
    Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara, Japan
    Anticancer Res 27:2657-65. 2007
    ..The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel...
  42. doi request reprint Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 7:599-606. 2008
    ....
  43. pmc MET amplification as a potential therapeutic target in gastric cancer
    Hisato Kawakami
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Oncotarget 4:9-17. 2013
    ..Furthermore, screening with a PCR-based copy number assay is an efficient way to reduce the number of patients requiring confirmation of MET amplification by FISH analysis...
  44. pmc SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer
    Kaoru Tanaka
    Department of Genome Biology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    PLoS ONE 7:e27922. 2012
    ..Our findings provide key glycobiological insight into SRPX2 in cancer cells and demonstrate that SRPX2 is a new member of the cancer-related proteoglycan family...
  45. doi request reprint A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
    Wataru Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Cancer Chemother Pharmacol 72:1063-71. 2013
    ..We conducted a phase I study to assess toxicities, pharmacokinetics, pharmacodynamics, and predictive biomarkers of nimotuzumab administered in Japanese patients with advanced solid tumors...
  46. doi request reprint Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung
    Hidemi Kiyota
    Department of Medical Oncology, Faculty of Medicine, Kinki University, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Chemother Pharmacol 71:859-65. 2013
    ..A phase I dose-escalation study was performed to investigate the safety and pharmacokinetics of the combination of S-1 and gefitinib in patients with pulmonary adenocarcinoma who had failed previous chemotherapy...
  47. doi request reprint MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations
    Junko Tanizaki
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 6:1624-31. 2011
    ..We examined the antitumor action of the MET-TKI crizotinib (PF-02341066) in lung cancer cells that are positive or negative for MET amplification or mutation...
  48. doi request reprint Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401)
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 5:105-9. 2010
    ..We have performed a multicenter phase II trial to evaluate the efficacy and safety of amrubicin for patients with previously treated non-small cell lung cancer (NSCLC)...
  49. doi request reprint Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B
    Hidetoshi Hayashi
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Breast Cancer 20:131-6. 2013
    ....
  50. doi request reprint Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors
    Taroh Satoh
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Clin Cancer Res 15:3872-80. 2009
    ..The aim of this study was to determine the maximum tolerated dose (MTD) and to assess the safety, pharmacokinetics, and antitumor activity of YM155 in patients with advanced refractory solid tumors...
  51. pmc HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
    Naoki Takegawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Oncotarget 7:3453-60. 2016
    ..The aim of this study was to detect HER2 amplification in circulating tumor DNA (ctDNA) from patients with CRC and acquired resistance to anti-EGFR antibody therapy...
  52. doi request reprint A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer
    Kazuko Sakai
    Department of Genome Biology, Kinki University, Faculty of Medicine, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 7:913-8. 2012
    ..However, the currently available assays for the detection of the different variants of EML4-ALK have limitations...
  53. doi request reprint A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
    Yoshikazu Hasegawa
    Department of Medical Oncology, Kishiwada City Hospital, Osaka, Japan
    Invest New Drugs 31:599-604. 2013
    ....
  54. doi request reprint Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
    Koichi Azuma
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohnohigashi, Osakasayama, Osaka 589 8511, Japan
    Biochem Biophys Res Commun 407:219-24. 2011
    ....
  55. doi request reprint Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer
    Ken Takezawa
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan
    Clin Cancer Res 17:2140-8. 2011
    ..The purpose of the present study was to characterize the mechanism of malignant transformation by EML4-ALK...
  56. pmc TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation
    Wataru Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:2785-92. 2010
    ..The addition of TAK-701 to gefitinib is a promising strategy to overcome EGFR-TKI resistance induced by HGF in NSCLC with an activating EGFR mutation...
  57. doi request reprint Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer
    Ryotaro Morinaga
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Sci 99:2455-60. 2008
    ..009) but not with FISH positivity (P = 0.266). Our results therefore suggest the existence of a significant association between EGFR mutation and EGFR amplification in patients with advanced NSCLC...
  58. doi request reprint Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells
    Tsutomu Iwasa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Clin Cancer Res 15:5117-25. 2009
    ..We have now investigated the effect of CP-751,871, a fully human monoclonal antibody specific for IGF-IR, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to radiation...
  59. ncbi request reprint Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
    Takafumi Okabe
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Cancer Res 67:2046-53. 2007
    ..These results reveal distinct biochemical properties of endogenous mutant forms of EGFR expressed in NSCLC cell lines and may have implications for treatment of this condition...
  60. doi request reprint Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations
    Kunio Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Cancer Res 70:10402-10. 2010
    ..Furthermore, they suggest that simultaneous interruption of the PI3K-AKT-survivin and MEK-ERK-BIM signaling pathways is responsible for EGFR-TKI-induced apoptotic death in these cells...
  61. doi request reprint Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer
    Masayuki Takeda
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 73:103-9. 2011
    ..Tumor expression levels of TS and DPD are predictive of response to S-1-carboplatin chemotherapy in patients with advanced NSCLC...
  62. doi request reprint The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF
    Takeshi Yoshida
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    FEBS Lett 582:4125-30. 2008
    ..Our findings shed light on the mechanism by which monoclonal antibodies to EGFR might augment the efficacy of cisplatin...
  63. doi request reprint Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed
    Hidetoshi Hayashi
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Int J Clin Oncol 15:497-9. 2010
    ..Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection...
  64. doi request reprint FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth
    Hiroyasu Kaneda
    Department of Genome Biology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Cancer Res 70:2053-63. 2010
    ..In conclusion, FOXQ1 is overexpressed in CRC and enhances tumorigenicity and tumor growth presumably through its angiogenic and antiapoptotic effects. Our findings show that FOXQ1 is a new member of the cancer-related FOX family...
  65. pmc A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
    H Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 103:6-11. 2010
    ..This study aimed to evaluate the safety and efficacy of dose-dense weekly chemotherapy, followed by resection and/or thoracic radiotherapy...
  66. ncbi request reprint Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement
    Hidetoshi Hayashi
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Osaka, Japan
    Anticancer Res 32:4533-7. 2012
    ....
  67. doi request reprint Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors
    Toshio Shimizu
    Department of Medical Oncology, Kinki University School of Medicine, Ohno Higashi, Osaka Sayama, Japan
    Cancer Chemother Pharmacol 65:243-50. 2010
    ..We have performed a phase I study to determine the safety profile, pharmacokinetics, and antitumor activity of D-19575 in Japanese patients with advanced solid tumors..
  68. doi request reprint Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan Center for Clinical and Translational Research, Faculty of Medicine, Kyusyu University Hospital, Fukuoka, Japan Department of Internal Medicine, Suita Municipal Hospital, Osaka, Japan Department of Medical Oncology, Nara Hospital, Kinki University Faculty of Medicine, Nara, Japan Department of Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Fukuoka, Japan Department of Medical Oncology, Kishiwada Municipal Hospital, Osaka, Japan Department of Thoracic Oncology, Kansai Medical University, Hirakata Hospital, Osaka, Japan Department of Medical Oncology, National Kyushu Cancer Centre, Fukuoka, Japan Department of Medical Oncology, National Kyushu Cancer Centre, Fukuoka, Japan Nippon Boehringer Ingelheim Co Ltd, Medical Development Division, Hyogo, Japan and Clinical Pharmacokinetics Pharmacodynamics Department, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    J Thorac Oncol 10:346-52. 2015
    ..This phase I, open-label study evaluated the safety/tolerability and maximum tolerated dose of second-line nintedanib combined with docetaxel in Japanese patients with advanced non-small-cell lung cancer...
  69. ncbi request reprint Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer
    Kimio Yonesaka
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Anticancer Res 35:1683-9. 2015
    ....
  70. ncbi request reprint Pemetrexed-induced edema of the eyelid
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 54:241-2. 2006
    ..We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known...
  71. doi request reprint Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 3:1073-5. 2008
    ..Carboplatin and etoposide chemotherapy combined with HD thus allowed the drugs to achieve an appropriate area under the concentration-time curve and sufficient efficacy in a small cell lung cancer patient with chronic renal failure...
  72. doi request reprint Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial
    Masayuki Takeda
    Department of Medical Oncology, Faculty of Medicine, Kinki University, Osaka, Japan
    Cancer 122:1050-9. 2016
    ..However, there has been no evidence to support the use of bevacizumab beyond disease progression in such patients...
  73. doi request reprint Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer
    Kunio Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, 589 8511, Japan
    Invest New Drugs 31:1364-6. 2013
    ....
  74. doi request reprint Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement
    Masayuki Takeda
    Department of Medical Oncology, Kinki University Faculty of Medicine, Ohno Higashi, Osaka Sayama, Osaka, Japan
    J Thorac Oncol 8:654-7. 2013
    ..However, subsequent chemotherapy has not been optimized in these patients...
  75. ncbi request reprint Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience
    Toshio Shimizu
    Department of Medical Oncology, Kinki University Nara Hospital, 1248 1 Otoda cho, Ikoma, Nara, 630 0293, Japan
    Int J Clin Oncol 12:218-23. 2007
    ..The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer. In Japan, oxaliplatin was approved in April 2005...
  76. doi request reprint Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors
    Isamu Okamoto
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan
    Cancer Sci 103:2135-8. 2012
    ..In conclusion, elpamotide is well tolerated and our biomarker analysis indicates that this anti-angiogenic vaccine is biologically active. Clinical trial registration no. UMIN000008336...
  77. doi request reprint Perirenal hematoma associated with bevacizumab treatment
    Hidetoshi Hayashi
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 30:808-9. 2012
    ..Although the appropriate modification of bevacizumab treatment in the setting of perirenal hematoma is still unclear, physicians should be aware of this potential bevacizumab-associated bleeding complication...
  78. doi request reprint Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer
    Hisato Kawakami
    Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka Sayama, Japan
    Eur J Cancer 49:3003-9. 2013
    ..With the increasing availability of active agents, the importance of postprogression survival (PPS) has been recognised for several malignancies. However, little is known of PPS in advanced gastric cancer...
  79. pmc Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG
    Masayuki Takeda
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    BMC Cancer 12:327. 2012
    ....
  80. ncbi request reprint Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation
    Ryotaro Morinaga
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Lung Cancer 58:411-3. 2007
    ..This case suggests that the activating EGFR mutations may confer the pathogenesis of a subset of SCLC...
  81. ncbi request reprint Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 25:499-504. 2007
    ..6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer...
  82. ncbi request reprint Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
    Takayasu Kurata
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 1:684-91. 2006
    ....
  83. doi request reprint SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion
    Kaoru Tanaka
    Department of Genome Biology, Kinki University School of Medicine, Osaka Sayama, Osaka, Japan
    Int J Cancer 124:1072-80. 2009
    ..In conclusion, the overexpression of SRPX2 enhances cellular migration and adhesion in gastric cancer cells. Here, we report that the biological functions of SRPX2 include cellular migration and adhesion to cancer cells...
  84. ncbi request reprint Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells
    Masato Ikeda
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Cancer Lett 248:292-8. 2007
    ..Furthermore, depletion of survivin resulted in G(2)-M arrest, suggesting that down-regulation of survivin by p53 contributes to the p53-dependent G(2)-M checkpoint triggered by DNA damage...
  85. doi request reprint Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production
    Ken Takezawa
    Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    J Thorac Oncol 3:187-9. 2008
    ..Furthermore, the tumor was confirmed immunohistochemically to produce AFP. To our knowledge, this is the first report of a LCNEC that produces AFP...
  86. ncbi request reprint Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer
    Isamu Okamoto
    Department of Respiratory Medicine, Kumamoto University, Kumamoto, Japan
    Jpn J Clin Oncol 35:188-94. 2005
    ..The efficacy and safety of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced NSCLC were evaluated in a phase II trial...
  87. ncbi request reprint Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer
    Isamu Okamoto
    Department of Respiratory Medicine, Graduate School of Medical Science, Kumamoto University, Japan
    Cancer Chemother Pharmacol 57:282-8. 2006
    ..The recommended phase II dose of amrubicin for patients with lung cancer refractory to standard chemotherapy is thus 35 mg/m(2) once a day for three consecutive days every 3 weeks...
  88. doi request reprint Reversible posterior leukoencephalopathy syndrome and trastuzumab
    Hiroyasu Kaneda
    Department of Medical Oncology, Kinki University Faculty of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Invest New Drugs 30:1766-7. 2012
    ..Given the increasing use of trastuzumab in patients with breast cancer, gastric cancer, or other solid tumors, physicians should be aware of this syndrome associated with acute hypertension during trastuzumab treatment...
  89. ncbi request reprint [Molecular targeting therapy for treatment of non-small-cell lung carcinoma]
    Isamu Okamoto
    Dept of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
    Gan To Kagaku Ryoho 35:1303-9. 2008
  90. ncbi request reprint [Cancer of unknown primary site-current status and future direction]
    Yasuko Ichikawa
    Dept of Medical Oncology, Kinki University School of Medicine, Japan
    Gan To Kagaku Ryoho 36:907-9. 2009
    ..Those are valuable for final diagnosis of primary site determination. Systemic chemotherapy is applied in many cases, but the standard therapeutic strategy has not yet been determined...
  91. pmc The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
    Isamu Okamoto
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Ther Adv Med Oncol 2:301-7. 2010
    ....
  92. pmc A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)
    H Kunitoh
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 100:464-9. 2009
    ..This medium-sized trial failed to show statistical significance in the primary end point. Although ipc BLM appeared safe and effective in the management of MPE, the therapeutic advantage seems modest...
  93. ncbi request reprint Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients
    Yusuke Matsunaga
    Department of Pharmacy, Kumamoto University Hospital, Kumamoto 860 8556, Japan
    Ther Drug Monit 28:76-82. 2006
    ..There is a possibility that monitoring of the plasma concentrations of amrubicin and amrubicinol may provide an efficient tool for establishing the optimal dosage of amrubicin in each patient...
  94. ncbi request reprint Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer
    Jun Araki
    Department of Respiratory Medicine, Yamaguchi Prefectural Hospital, 77 Osaki, Hofu, Yamaguchi 0835 4411, Japan
    Lung Cancer 48:141-4. 2005
    ..This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC...
  95. ncbi request reprint Successful treatment of primary pulmonary angiosarcoma
    Keisuke Kojima
    Department of Respiratory Medicine, Graduate School of Medical Science, Kumamoto University, 1 1 1 Honjo, Kumamoto 860 0811, Japan
    Chest 124:2397-400. 2003
    ..The patient remains well without signs of recurrence 1 year after initial presentation. This combination therapy may be a promising strategy to prolong the survival of patients with primary pulmonary angiosarcoma...
  96. ncbi request reprint Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?
    Isamu Okamoto
    Intern Med 42:926-7. 2003
  97. ncbi request reprint Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer
    Isamu Okamoto
    First Department of Internal Medicine, Kumamoto University School of Medicine, 1 1 1 Honjo, Kumamoto 860 0811, Japan
    Lung Cancer 40:339-42. 2003
    ..This case is the first reported of respiratory failure after ZD1839 treatment in a patient with NSCLC. Physicians should therefore be aware of the potential pulmonary toxicity of ZD1839...
  98. ncbi request reprint Expression of constitutively activated EGFRvIII in non-small cell lung cancer
    Isamu Okamoto
    Department of Microbiology and Immunology, Kimmel Cancer Institute, Philadelphia, PA 19107, USA
    Cancer Sci 94:50-6. 2003
    ..Our results suggest that the sustained activation of EGFRvIII is implicated in the pathogenesis of NSCLC and thus EGFRvIII is a potential therapeutic target in this challenging disease...
  99. ncbi request reprint Elevated JNK activation contributes to the pathogenesis of human brain tumors
    Marc A Antonyak
    The Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, PA 19107, USA
    Oncogene 21:5038-46. 2002
    ..These findings demonstrate that enhanced JNK activation is frequently found in primary brain tumors and that this activation contributes to phenotypes related to transformation...
  100. pmc Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors
    Isamu Okamoto
    Department of Microbiology and Immunology, Kimmel Cancer Institute, BLSB 2002, Thomas Jefferson University, 233 S 10th St, Philadelphia, PA 19107, USA
    Am J Pathol 160:441-7. 2002
    ..Tumors expressing a CD44 splice variant showed a significantly higher incidence of enhanced CD44 cleavage. The wide prevalence of CD44 cleavage suggests that it plays an important role in the pathogenesis of human tumors...